Adrian F. Ochsenbein

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Control of Early Viral and Bacterial Distribution and Disease by Natural Antibodies

Adrian F. Ochsenbein, Thomas Fehr, Claudia Lutz et al. · Science · 1999 · 911 citations

Life Sciences, Immunology, Microbiology +17

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction

Adrian F. Ochsenbein, Sophie Sierro, Bernhard Odermatt et al. · Nature · 2001 · 490 citations

Life Sciences, Immunology, Oncology +17

Immune surveillance against a solid tumor fails because of immunological ignorance

Adrian F. Ochsenbein, Paul Klenerman, Urs Karrer et al. · Proceedings of the National Academy of Sciences · 1999 · 453 citations · Full text

Life Sciences, Immunology, Oncology +17

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

Roger Stupp, Monika E. Hegi, Bart Neyns et al. · Journal of Clinical Oncology · 2010 · 443 citations · Full text

Medicine, Oncology, Pharmacotherapy +16